| Pharmaceutical Information |
| Drug Name |
Biguanide |
| Drug ID |
BADD_D00273 |
| Description |
Biguanide has been investigated for the treatment of Diabetes Mellitus. |
| Indications and Usage |
Not Available |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB13100
|
| KEGG ID |
Not Available
|
| MeSH ID |
D001645
|
| PubChem ID |
5939
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
FB4Q52I9K2
|
| Synonyms |
Biguanides | Biguanide |
|
| Chemical Information |
| Molecular Formula |
C2H7N5 |
| CAS Registry Number |
56-03-1 |
| SMILES |
C(=NC(=N)N)(N)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Anaphylactic shock | 24.06.02.004; 10.01.07.002 | - | - | Not Available | | Angioedema | 10.01.05.009; 22.04.02.008; 23.04.01.001 | - | - | Not Available | | Injection site pain | 12.07.03.011; 08.02.03.010 | - | - | Not Available | | Pain | 08.01.08.004 | - | - | | | Urticaria | 23.04.02.001; 10.01.06.001 | - | - | |
|
The 1th Page
1
Total 1 Pages
|
|
